Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 1:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 816 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Butyrate Clear all
Recruiting Phase 2 Interventional

Ca-Mg Butyrate in Gulf War Illness

NCT05367245
View directory record Official record
Conditions
Gulf War Illness, Chronic Fatigue, Neurocognitive Dysfunction
Interventions
Cal-Mag Butyrate, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Long Beach, California • Miami, Florida • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 24, 2026, 1:46 AM EDT
Withdrawn Phase 1 Interventional

Study of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia

NCT00872976
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Dasatinib, Combination of Bendamustine + Dasatinib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
New Hyde Park, New York • Columbus, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 22, 2013 · Synced Oct 24, 2026, 1:46 AM EDT
Active, not recruiting Phase 1 Interventional Results available

Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma

NCT03696784
View directory record Official record
Conditions
Lymphoma, Lymphoma, B-Cell, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases
Interventions
iC9-CAR19 T cells, Bendamustine, Fludarabine, AP1903, Cyclophosphamide
Biological · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2040
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 24, 2026, 1:46 AM EDT
Completed Phase 4 Interventional Results available

Preoperative Pain Control in Gastric Bypass Surgery Patients

NCT01801189
View directory record Official record
Conditions
Post-operative Pain
Interventions
Pregabalin, Placebo (for Pregabalin)
Drug
Lead sponsor
Legacy Health System
Other
Eligibility
18 Years to 70 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 14, 2022 · Synced Oct 24, 2026, 1:46 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

NCT01073163
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma
Interventions
Bendamustine, Rituximab
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
36
States / cities
Tucson, Arizona • Little Rock, Arkansas • Fullerton, California + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2014 · Synced Oct 24, 2026, 1:46 AM EDT
Recruiting Phase 1 Interventional

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

NCT06191887
View directory record Official record
Conditions
B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Small Lymphocytic Lymphoma, Refractory Transformed Chronic Lymphocytic Leukemia
Interventions
Autologous BAFFR-targeting CAR T Cells, Bendamustine, Biopsy, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Computed Tomography, Cyclophosphamide, Echocardiography, Fludarabine, Leukapheresis, Magnetic Resonance Imaging, Positron Emission Tomography
Biological · Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2040
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 24, 2026, 1:46 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of High Dose Baclofen for Alcohol Dependence

NCT01980706
View directory record Official record
Conditions
Alcoholism
Interventions
Baclofen, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Oct 24, 2026, 1:46 AM EDT
Suspended Phase 3 Interventional

A Novel Approach to Infantile Spasms

NCT03347526
View directory record Official record
Conditions
Infantile Spasm
Interventions
Cosyntropin Injectable Suspension, 1 mg/mL, Cosyntropin Injectable Suspension 1 MG/ML + vigabatrin, Vigabatrin
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
2 Months to 2 Years
Enrollment
394 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
14
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Oct 24, 2026, 1:46 AM EDT
Terminated Phase 2 Interventional Results available

Phase II Study to Evaluate Fenofibrate Therapy in Patients With Smoldering or Symptomatic Multiple Myeloma

NCT01965834
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Fenofibrate
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 24, 2026, 1:46 AM EDT
Completed Phase 2 Interventional Results available

Endothelial Function, Lipoproteins, and Inflammation With Low HDL Cholesterol in HIV: ER Niacin Versus Fenofibrate

NCT01426438
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Niacin, Aspirin, Fenofibrate
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • Torrance, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Oct 24, 2026, 1:46 AM EDT
Completed Phase 1 Interventional Results available

A Study of Obinutuzumab (GA101; RO5072759) in Combination With Chemotherapy in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GALTON)

NCT01300247
View directory record Official record
Conditions
Lymphocytic Leukemia, Chronic
Interventions
Fludarabine, Obinutuzumab, Bendamustine, Cyclophosphamide
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
18
States / cities
Huntsville, Alabama • Duarte, California • La Jolla, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Oct 24, 2026, 1:46 AM EDT
Enrolling by invitation Phase 4 Interventional

Enhanced Recovery After Surgery (ERAS) in Live Donor Kidney Transplant Recipients

NCT06997016
View directory record Official record
Conditions
Postoperative Pain
Interventions
pre-operative carbohydrate drink, Acetaminophen, Gabapentin, Bupivacaine, Ambulation
Dietary Supplement · Drug · Other
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 24, 2026, 1:46 AM EDT
Terminated Phase 4 Interventional

Postoperative Tramadol/Gabapentin/Ibuprofen Versus Tramadol/Placebo/Ibuprofen

NCT02076893
View directory record Official record
Conditions
Pain
Interventions
gabapentin, Tramadol, Ibuprofen, Placebo
Drug
Lead sponsor
Children's Hospitals and Clinics of Minnesota
Other
Eligibility
4 Years to 15 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Oct 24, 2026, 1:46 AM EDT
Completed Phase 4 Interventional Results available

Adherence to Topical Hydrocortisone 17-butyrate 0.1% (Locoid®) Using Different Vehicles in Adults With Atopic Dermatitis

NCT00693693
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
hydrocortisone 17-butyrate 0.1% Cream preparation, hydrocortisone 17-butyrate 0.1% Ointment preparation, hydrocortisone 17-butyrate 0.1% Lipocream preparation
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 24, 2026, 1:46 AM EDT
Recruiting Early Phase 1 Interventional

Synaptic Mechanisms of Continuous Theta Burst Stimulation in Depression

NCT07560878
View directory record Official record
Conditions
Major Depression
Interventions
D-Cycloserine (DCS), Continuous theta-burst stimulation (cTBS), Transcranial Magnetic Stimulation Sham, Memantine, Lorazepam (drug), Baclofen, Placebo
Drug · Device
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 24, 2026, 1:46 AM EDT
Terminated Phase 4 Interventional Results available

Pregabalin for Abdominal Pain From Adhesions

NCT00310765
View directory record Official record
Conditions
Abdominal Pain, Surgical Adhesions
Interventions
Pregabalin 75 or 150 mg BID for 7 weeks followed by open label pregabalin 150 mg BID for 4 weeks, Placebo first followed by open label pregabalin
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
West Bloomfield, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 24, 2026, 1:46 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia

NCT01188681
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia (CLL)
Interventions
TRU-016 and bendamustine, Bendamustine, 15 mg/kg TRU-016 and bendamustine, 20 mg/kg TRU-016 and bendamustine
Drug
Lead sponsor
Aptevo Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
9
States / cities
Denver, Colorado • Augusta, Georgia • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Oct 24, 2026, 1:46 AM EDT
Terminated Phase 4 Interventional Results available

Effect of Gabapentin on Orthopedic Pain

NCT01546857
View directory record Official record
Conditions
Degenerative Arthritis and Postoperative Pain
Interventions
Placebo, Gapabentin
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Oct 24, 2026, 1:46 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

NCT02763319
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma
Interventions
Rituximab (RTX), Tafasitamab, Bendamustine (BEN)
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
18
States / cities
Anaheim, California • Bakersfield, California • Burbank, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 24, 2026, 1:46 AM EDT
Completed Phase 3 Interventional

To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.

NCT00141336
View directory record Official record
Conditions
Seizure Disorder, Partial
Interventions
Pregabalin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
97
States / cities
Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 71 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2007 · Synced Oct 24, 2026, 1:46 AM EDT
Completed Phase 2 Interventional Results available

Gabapentin Treatment of Cannabis Dependence

NCT00395044
View directory record Official record
Conditions
Cannabis Dependence
Interventions
Placebo, Gabapentin
Drug
Lead sponsor
The Scripps Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 24, 2026, 1:46 AM EDT
Terminated Phase 3 Interventional Results available

Perioperative Analgesia Using Gabapentin in Head and Neck Cancer Surgery

NCT03682367
View directory record Official record
Conditions
Cancer of Head and Neck, Narcotic Use
Interventions
Gabapentin, Placebo - Concentrate
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2021 · Synced Oct 24, 2026, 1:46 AM EDT
Completed Phase 3 Interventional

A Study of Single-Dose Gabapentin in Subjects With Transient Insomnia Induced by a Sleep Phase Advance

NCT00666939
View directory record Official record
Conditions
Transient Insomnia
Interventions
Gabapentin, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
773 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
10
States / cities
San Diego, California • Ocala, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 24, 2026, 1:46 AM EDT
Terminated Phase 2 Interventional Results available

Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma

NCT01438177
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Velcade, Cyclophosphamide, Chloroquine
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Oct 24, 2026, 1:46 AM EDT